Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases

Rades, Dirk; Hansen, Heinke C.; Schild, Steven E.

doi:10.3390/cancers11020233

Cited by 8 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the MST was 11.87 months, which is relatively better than in previous reports (14,20). This was mainly due to the retrospective design and an inherent selection bias.…”

Section: Discussioncontrasting

confidence: 65%

“…Patients were then grouped into three prognostic stratifications according to their total points (18). However, this system is complex and has limited predictive ability, and is thus not often used in clinical practice (19,20). In 2018, Bernhardt et al proposed a novel index called the BMS-Score, which consists of only three factors: KPS, synchronous BM or metachronous BM, and ECM state (15).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of a novel prognostic index: BMS-Score for patients with brain metastases of small cell lung cancer

Cao

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: A new disease-specific prognostic score (Disease-specific Prognostic Score for Patients With Brain Metastases From Small-cell Lung Cancer termed BMS-Score) was published to clarify the prognosis of patients with brain metastasis (BM) of small cell lung cancer (SCLC) treated with whole brain radiotherapy (WBRT). The purpose of the present study was to validate the prognostic value of the newly proposed BMS-Score through comparison with three other previously published prognostic indices. Methods: In total, 451 patients with BM of SCLC treated with WBRT at the Shanxi Province Cancer Hospital from January 2010 to December 2019 were included. The clinical characteristics of all patients were recorded and follow-up was through April 2020. Overall survival (OS) was calculated by Kaplan-Meier analysis, and univariate and multivariate analyses were used to calculate the prognostic cofactors. The concordance index (C-index) was used to assess the prognostic value of the following four prognostic systems: recursive partitioning analysis (RPA), diagnosis-specific graded prognostic assessment (DS-GPA), basic score for brain metastases (BSBM), and the newly proposed BMS-Score. Results: The independent factors affecting the prognosis of SCLC patients with BM included the Karnofsky performance score (KPS), number of brain metastases, extracranial metastases (ECM) state, and whether treatment had been received before BM. RPA, BSBM, DS-GPA, and BMS-Score log-rank test P values were all less than 0.001 among each group (P<0.001). The C-indices of the four groups were 0.554, 0.584, 0.588, and 0.643, respectively. Conclusions: The four prognostic scoring systems exhibited medium predictive value for SCLC. The BMS-Score had the best applicability compared with the other three prognosis indices.

show abstract

Section: Discussioncontrasting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Validation of a novel prognostic index: BMS-Score for patients with brain metastases of small cell lung cancer

Cao

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…In the second part of the present study, the new scoring tool was compared to three existing diagnosis-specific instruments designed from patients with cerebral metastases from SCLC of any age (7)(8)(9). The four tools were compared regarding the PPVs to correctly identify patients dying within 6 months and patients surviving for at least 6 months.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the new tool was compared to existing diagnosis-specific instruments created for patients with cerebral metastases from SCLC of any age, namely the updated diagnosis-specific graded prognostic assessment classification (DS-GPA), the Rades-SCLC score and the WBRT-30-SCLC score (7)(8)(9). Comparisons were performed with respect to the positive predictive values (PPVs) to correctly identify patients who die within 6 months following WBI (comparison of the least favorable groups) and patients who survive for at least 6 months following WBI (comparison of the most favorable groups).…”

Section: Methodsmentioning

confidence: 99%

“…To support physicians during the process of treatment personalization for elderly patients with cerebral metastases from SCLC, a simple and specific tool was developed for estimation of the remaining lifespan of such patients. In addition, this new tool was compared to instruments that were created for patients with cerebral metastases from SCLC of any age and not specifically for elderly patients (7)(8)(9). We present the following article in accordance with the TRIPOD reporting checklist (available at http://dx.doi.org/10.21037/tlcr-20-327).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of a multivariable prediction model to estimate the remaining lifespan of elderly patients with cerebral metastases from small-cell lung cancer

Rades

Nguyen

Schild

2020

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: Prognostic tools estimating survival of elderly patients with cerebral metastases from smallcell lung cancer (SCLC) improve treatment personalization. A specific tool for these patients was developed and compared to existing instruments.Methods: One-hundred-and-forty elderly patients (≥65 years) receiving whole-brain irradiation (WBI) for cerebral metastases from SCLC were retrospectively evaluated. WBI-program, age, gender, Karnofsky performance score, number of cerebral lesions, extracerebral metastases, and interval between SCLCdiagnosis and WBI were investigated. Characteristics significantly associated with survival in the multivariate analysis were used for the tool. Scoring points were calculated by dividing 6-month survival rates (%) by 10 and added for patient scores. The tool was compared to existing diagnosis-specific instruments including updated diagnosis-specific graded prognostic assessment (DS-GPA), Rades-SCLC and WBRT-30-SCLC.Results: In the multivariate analysis, KPS (P<0.001), number of cerebral lesions (P=0.013) and extracerebral metastases (P=0.049) were significantly associated with survival. Patient scores of 2 (n=37), 5 (n=69), 8 (n=20) and 11 (n=14) points were obtained; 6-month survival rates were 0%, 9%, 50% and 79% (P<0.001). The positive predictive value (PPV) of the worst group (2 points) to identify patients dying ≤6 months was 100%; PPVs of updated DS-GPA, Rades-SCLC and WBRT-30-SCLC were 94%, 100% and 94%. PPV of the best group (11 points) to identify patients surviving ≥6 months was 79%; PPVs of updated DS-GPA, Rades-SCLC and WBRT-30-SCLC were 86%, 79% and 100%. Conclusions:The most precise instruments were the new tool and Rades-SCLC for identification of patients dying ≤6 months, and the WBRT-30-SCLC to identify patients surviving ≥6 months.

show abstract

Radiation Therapy for Brain Metastases

2022

View full text Add to dashboard Cite

Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases

Cited by 8 publications

References 27 publications

Validation of a novel prognostic index: BMS-Score for patients with brain metastases of small cell lung cancer

Validation of a novel prognostic index: BMS-Score for patients with brain metastases of small cell lung cancer

Development of a multivariable prediction model to estimate the remaining lifespan of elderly patients with cerebral metastases from small-cell lung cancer

Radiation Therapy for Brain Metastases

Contact Info

Product

Resources

About